The Osteoporosis Drugs Market is anticipated to grow significantly, with an expected market size of USD 9.8 billion by 2032, up from USD 7 billion in 2022, reflecting a CAGR of 3.5% during the forecast period from 2023 to 2032. This growth is driven by several factors, including the increasing prevalence of osteopor.
Press release - ABNewswire - Diabetic Foot Ulcers Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Medline, B. Braun, Organogenesis, 3M, Smith & Nephew - published on openPR.com